Randomized controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial

Lancet

Volumn 348, Issue 9029, 1996, Pages 708-713

  Forrest, A Patrick ^a   Stewart, Helen J ^a   Everington, Dawn ^b   Prescott, Robin J ^b   McArdle, Colin S ^c   Harnett, Adrian N ^d   Smith, David C ^e   George, W David ^f  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e VICTORIA INFIRMARY   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; ADJUVANT THERAPY; BREAST TUMOR; FOLLOW UP; INCIDENCE; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RISK; SURVIVAL; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; SURVIVAL RATE; TAMOXIFEN;

EID: 0030583364     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02133-2     Document Type: Article

References (21)

1. Stewart HJ, Robinson SM. Recruitment to breast cancer trials. Lancet 1984; ii: 1096-97.
2. Veronesi U, Saccozzi R, Del Vecchio Met al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med. 305:1981;6-11.
3. Sarrazin D, Le M, Rouesse J, et al. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less: the experience of the Institut Gustave-Roussy. Cancer 1984; 53: 1209-13.
4. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomised clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 132: 665-73.
5. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993; 341: 1293-98.
6. Hawkins RA, Black R, Steele RJC, Dixon JMJ, Forrest APM. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Br Cancer Res Treat 1981; 1: 245-51.
7. Leake RE, Habib F. Steroid hormone receptors: assay of characterisation. In: Green B, Leake R, eds. Steroid hormones: a practical approach. Oxford: IRL Press, 1987: 67-94.
8. Breast Cancer Trials Committee. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; ii: 171-75.
9. Stewart HJ, Prescott RJ, Forrest APM. Conservation therapy of breast cancer. Lancet 1989; ii: 168-69.
10. Mehta CR, Patel NR, Gray R. Computing and exact confidence interval for the common odds ratio in several 2×2 contingency tables. J Am Stat Assoc 1985; 80: 969-73.
11. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991; 338: 327-31.
12. Clark RM, McCulloch PB, Levine MN, et al. Randomised clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 1992; 84: 683-89.
13. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localised cancer of the breast. N Engl J Med 1993; 328: 1587-91.
14. Liljegren G, Holmberg L, Adami H-O, et al. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomised trial. J Natl Cancer Inst 1994; 86: 717-22.
15. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet. 339:1992;1-15.
16. International Breast Cancer Study Group. Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol. 1:1990;30-35.
17. Veronesi V, Volterrani F, Luini A, et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 1990; 26: 671-73.
18. Macmillan RD, Purushotham AD, Mallon E, Ramsay G, George WD Breast-conserving surgery and tumour bed positivity in patients with breast cancer. Br J Surg. 81:1994;56-58.
19. van Dalen R, Bates A, Dhesi I, Bates T, Houghton J. Positive cavity biopsy does not predict early local relapse for patients treated by local excision for early breast cancer. Breast 1995; 4: 231 (abstr no 15).
20. Hayward JL. The Guy's Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen W, eds. Conservative management of breast cancer. Philadelphia: Lippincott, 1983: 77-90.
21. Veronesi U, Marubini E, Del Vecchio Met al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 87:1995;19-27.